

CURRICULUM VITAE

Maria Teresa Scupoli

Current positions

- Full Professor of Cellular and Experimental Biology, School of Medicine, Dept. of Engineering for Innovation Medicine *since 2025*
- Head of the Research Centre LURM (Laboratorio Universitario di Ricerca Medica) (<https://lurm.univr.it/>), University of Verona *since 2004*
- President of ISCCA (Italian Society for Cytometric Cell Analysis) *since 2022*
- Member of the Governing Board of the "Committee for Biological and Bioinformatic Studies", FIL (Fondazione Italiana Linfomi) *since 2023*

Education

- | | |
|-----------|---|
| 1997-2002 | PhD in Biotechnology Applied to Biomedical Science, University of Verona
Research: Immunobiology, Experimental Hematology. Functional interplaying between normal immature T lymphocytes and bystander cells in thymic microenvironment. |
| 1994-1997 | Board certified in Genetics with full marks and honors, University of Bologna
Research: Immunobiology. Effects of thymic microenvironment on immature T-cell biology: the regulatory role of NF- κ B. |
| 1982-1987 | Master's Degree in Biology with full marks and honors, University of Bologna
Research: Biochemistry, Biophysics. |

Past experience and employment

- | | |
|------------|---|
| 2018- 2025 | Associate Professor of Cellular and Experimental Biology, School of Medicine, Dept. of Neurosciences, Biomedicine, and Movement, University of Verona. |
| 2019-2022 | Member of the Governing Board of ISCCA (Italian Society for Cytometric Cell Analysis). |
| 2012-2015 | Member of the Board of Directors, University of Verona. |
| 2004-2018 | Staff Scientist, Research Centre LURM (Laboratorio Universitario di Ricerca Medica), University of Verona. |
| 2002-2003 | Research Assistant, Department of Medicine, Hematology Section, University of Verona.
Research: Experimental Hematology. Influence of neoplastic microenvironments on the biology of leukemic states. |
| 2000 | Academic Visitor, Department of Immunology, Faculty of Medicine. Imperial College School of Medicine, London. Research: Immunobiology, Experimental Hematology. Influence of thymic microenvironment on the biology of leukemic states. |
| 1995-1996 | ISS (Italian Institute of Health) Research Fellow, Department of Medicine, University of Verona. |

Research: Immunobiology. Functional interplaying between thymic epithelial cells and immature T lymphocytes in the thymic microenvironment: role of adhesion molecules and NF-κB proteins in gene transcription and cell survival.

1991-1993 AIRC (Italian Association for Cancer Research) Fellow, Department of Medicine, University of Verona. Research: Immunogenetics, Gene expression. Regulation of MHC class-II antigen expression in normal and neoplastic states.

Awards

Award GILEAD Sciences. "Fellowship Program". An antioxidant signature as a newer prognostic model in chronic lymphocytic leukemia. 2019-2020.

Award "Alessandro Moretta" best oral presentation at the ISCCA Conference (Italian Society for Cytometric Cell Analysis), November 8-10, 2018. Rome.

Award for the best oral abstract presentation at the ESCCA Conference (European Society for Clinical Cell Analysis), September 11-14, 2016. Edinburgh.

Award for a scientific contribute at the XVIII national Conference of the Italian Association for the Study of Pancreas, June 17-18, 1994. Milan.

Grants

2023-2026 European Union - Next Generation EU and Ministero della Salute - PNRR-TR1-2023-12378287. Integrated BCR signaling and genomics/transcriptomics to identify patients with MCL failing BTK-inhibitors. Role: senior investigator.

2022-2026 European Union - Next Generation EU and Ministero della Salute – PNRR PNC-E3-2022-23683266 PNC-HLS-DA, INNOVA. Role: co-principal investigator.

2021-2023 Fondazione Italiana Linfomi (FIL). Clinical and biological insights of first relapsed-refractory younger patients with mantle cell lymphoma (MCL): the MANTLE-FIRST^{BIO} study. Role: participant.

2019-2020 Award GILEAD Sciences. "Felloship Program". An antioxidant signature as a newer prognostic model in chronic lymphocytic leukemia. Role: Principal Investigator.

2016-2017 Fondazione Cariverona. Biomarkers in Oncology.. Role: participant.

2009-2016 AIRC (Associazione Italiana Ricerca sul Cancro). Regional research program 2008. An integrated approach to chronic lymphoproliferative disorders: B-CLL and virus-related neoplasia. Role: participant from 2009 to 2014; Principal Investigator from 2015 to 2016.

2009-2010 Fondazione Cariverona 2008. Autoimmunity in chronic lymphocytic leukemia. Leukemic mechanisms regulating differentiation and activation of T cells and dendritic cells. Role: Principal Investigator.

2007-2008 Ricerca Sanitaria Finalizzata Regionale 2006 - Progetto Istituto Oncologico Veneto (IOV). Razionalizzazione e standardizzazione di diagnosi e terapia della leucemia linfatica cronica: attivazione di una rete tra strutture ematologiche nella Regione Veneto. Role: participant.

2005-2007 COFIN/MIUR 40%. Mechanisms involved in immunoregulatory effects of human bone-marrow mesenchymal cells. Role: participant.

2004-2005 Fondazione Cariverona 2003. Microenvironment and tumor progression: the regulatory network induced by stromal cells. Biology and therapeutic application. Role: Principal Investigator.

Peer reviews

Ad hoc reviewer for scientific journals (*Blood, Leukemia, British Journal of Haematology, Redox Biology, Haematologica, Journal of Proteomics, Cells, Frontiers in Oncology, Frontiers in Immunology, Scientific Reports, Journal of Cellular and Molecular Medicine (JCMM), Cytometry part B, Journal of Translational Medicine, Leukemia Research, Cancers, Cancer Cell International, BMJ Open*) and for grant applications (*Leukaemia & Lymphoma Research (LLR), UK; HRZZ – Croatian Science Foundation, HR; Bloodwise, UK*).

Teaching experience: teachings

2023-present	Experimental Design. Master's degree in biology for Translational Research and Precision Medicine, University of Verona. Tenured Associate Professor (Full Professor since 2025).
2021-present	Biology. Master's degree in medicine and surgery, School of Medicine, University of Verona. Tenured Associate Professor (Full Professor since 2025).
2019- present	Applied Biology. Bachelor's degree in nursing, School of Medicine, University of Verona. Tenured Associate Professor (Full Professor since 2025).
2019- 2024	Flow Cytometry. PhD School of Life and Health Science, PhD program in Applied Life and Health Sciences, University of Verona Tenured Associate Professor.
2019- 2023	Applied Biology. Bachelor's degree in dental Hygiene. School of Medicine, University of Verona. Tenured Associate Professor.
2019-2022	Applied Biology. Master's Degree in Dentistry, School of Medicine, University of Verona. Tenured Associate Professor.
1996-1997	Immunology and Immunohematology. Bachelor's degree in nursing, School of Medicine, University of Verona. Lecturer and Faculty member.
1995-1997	Cell Culture Techniques. Bachelor's degree in laboratory Technician, School of Medicine, University of Verona. Lecturer and Faculty member.
1995- present	Supervisor of several Bachelor, Master, PhD, Residency Program Thesis, University of Verona, and University of Padova.

Meeting organizer and speaker

Invited Speaker: "Phosphospecific flow cytometry: at the crossroad between biochemistry and clinical applications at the single cell level". Conference: Advances in flow cytometry II: Multidisciplinary approach in an one health perspective. February 12-13, 2025. Roma, Italy.

Invited Speaker. "Signaling signatures in MCL failing BTK-inhibitors". Conference of the European Network on Mantle Cell Lymphoma. November 21-23, 2024. Lisbon, Portugal.

Scientific organizer. ISCCA (Italian Society for Cytometric Cell Analysis) Conference 2024. May 29-31, 2024. Verona, Italy.

Scientific committee. ISCCA (Italian Society for Cytometric Cell Analysis) Conference 2024. May 29-31, 2024. Verona, Italy.

Invited Speaker: "La citometria a flusso fosfo-specifica: all'incrocio tra biochimica e applicazioni cliniche a livello di singola cellula". Corso: Progressi in citometria a flusso: svelare le complessità delle applicazioni. February 29, 2024. Padova, Italy.

Invited Speaker: "Phospho-specific flow cytometry to functionally characterize oncogenic signaling in cancer". Corso di Perfezionamento CITOFLUORIMETRIA DI ULTIMA GENERAZIONE: Aspetti teorico-pratici e metodologie analitiche in ambito biomedico. September 26-30, 2022. Milan, Italy.

Scientific committee. ISCCA (Italian Society for Cytometric Cell Analysis) Conference 2022. May 25-27, 2022. Catania, Italy.

Scientific committee. "Webinars on Single-Cell Multiomics Analysis", Cytometry School of Urbino. May 4, 12, and 25, 2021.

Invited speaker. "Phospho-specific flow cytometry to unveil cancer heterogeneity". Webinars on Single-Cell Multiomics Analysis. May 25, 2021.

Scientific committee. ISCCA (Italian Society for Cytometric Cell Analysis) Virtual Conference 2021. May 19-21, 2021.

Invited speaker. "Single-cell analysis of CD20-mediated signaling pathway". ISCCA (Italian Society for Cytometric Cell Analysis) Virtual Conference 2020. November 5, 2020.

Scientific organizer. ISCCA (Italian Society for Cytometric Cell Analysis) Virtual Conference 2020. November 5, 2020.

Invited speaker. "Signaling pathways inhibition mediated by anti-CD20 antibodies in B-cell leukemia". ISCCA (Italian Society for Cytometric Cell Analysis) Conference. Plenary Session "Functional Biology"– July 6-9, 2019. Urbino, Italy.

Invited speaker. "Phosphospecific flow cytometry: at the crossroad between biochemistry and clinics at the single-cell level". ISCCA (Italian Society for Cytometric Cell Analysis) Conference. November 8-10, 2018. Rome, Italy.

Invited speaker. "Phosphoprotein Analysis", Course "Intracytoplasmic labeling". ISCCA (Italian Society for Cytometric Cell Analysis) Conference. November 8-10, 2018. Rome, Italy.

Speaker. "Characterization of redox signaling sensitivity associated with leukemia disease progression by phospho-specific flow cytometry". ESCCA (European Society for Clinical Cell Analysis) Conference. September 24-27, 2017. Thessaloniki, GR.

Speaker. "Phospho-specific flow cytometry for characterizing redox signaling sensitivity associated with leukemia disease progress". ISCCA (Italian Society for Cytometric Cell Analysis) Conference. May 8-10, 2017. Bologna, Italy.

Speaker. "Integrate single cell network profiling data of ERK signaling and mutations of SF3B1 gene refine prognosis in chronic lymphocytic leukemia". ESCCA (European Society for Clinical Cell Analysis) Conference. September 11-14, 2016. Edinburgh, UK.

Invited speaker. "Analysis of signaling profiles in chronic lymphocytic leukemia". ESCCA (European Society for Clinical Cell Analysis) Conference. October 30, 2015. Giardini Naxos (CT), Italy.

Invited speaker. "The tumor microenvironment: molecular cross-talk and new opportunity". New Perspectives in Hematology. September 26, 2014. Verona, Italy.

Scientific committee. Advanced course in flow cytometry: applications in Oncology and Immunology. May 22-23, 2012. Verona, Italy.

Invited speaker. "The single cell network profiling in the prognostic characterization of chronic lymphocytic leukemia". Advanced course in flow cytometry: applications in Oncology and Immunology. May 22-23, 2012. Verona, Italy.

Invited speaker. "Single-cell analysis of the B-cell receptor signaling profile in chronic lymphocytic leukemia." Discussiamone Insieme SIES (Società Italiana di Ematologia Sperimentale): Le Sindromi linfoproliferative croniche. November 24, 2011. Florence, Italy.

Invited speaker. "Phospho-flow in acute lymphoblastic leukemia" - Primo Congresso di Oncoematologia Molecolare. March 26-28, 2010. Torino, Italy.

Invited speaker. “Single-cell profiles of B-cell receptor phospho-protein networks associated with prognosis and progression in chronic lymphocytic leukemia”. Nodality Inc. December 22, 2009. South San Francisco, CA, USA.

Scientific societies

Biological Studies Committee, Fondazione Italiana Linfomi (FIL), since 2022.

FISMELAB (Federazione delle società scientifiche italiane nel settore della medicina di laboratorio) Board of Directors, since 2022.

ISAC (International Society for Advancement of Flow Cytometry), since 2022.

AIBG (Associazione Italiana di Biologia e Genetica), since 2018.

President of ISCCA since 2022; ISCCA Board of Directors 2019-2021; ISCCA (Italian Society for Cytometric Cell Analysis) member, since 2016.

ESCCA (European Society for Clinical Cell Analysis), since 2014.

SIES (Società Italiana di Ematologia Sperimentale), since 2007.

Publications

Author of 83 articles cited in PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=scupoli+m&sort=date>)

Total citations (Scopus): 3726

Hirsch (H) index (Scopus): 34

List of publications:

1. Quaglia FM, Gambino S, Galasso M, Vegliante MC, Visco C, **Scupoli MT**. B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma. *Cell Commun Signal*. 2025 Nov 11;23(1):486. doi: 10.1186/s12964-025-02468-6.PMID: 41219853. Review.
2. Caputo C, Donadelli M, **Scupoli M**, D'Arena G, Pietrantuono G, Giudice A, Giliberti A, Volpe S, Sperlongano R, Cautela D, Scafuri B, Facchiano A, Cossu AM, Bocchetti M, Misso G, Lombardi A, Caraglia M, Grimaldi A. Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways. *Mol Ther Oncol*. 2025 Sep 2;33(4):201048. doi: 10.1016/j.omton.2025.201048. eCollection 2025 Dec 18.PMID: 41035777.
3. Galasso M, Salaorni V, Moia R, Mozzo V, Lovato E, Cosentino C, Perbellini O, Gambino S, Lovato O, Carazzolo ME, Ferrarini I, Quaglia FM, Donadelli M, Romanelli MG, Visco C, Krampera M, Gaidano G, **Scupoli MT**. CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia. *Hematol Oncol*. 2024 Nov;42(6):e70002. doi: 10.1002/hon.70002.PMID: 39540258.
4. Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, Giacobazzi L, Caligola S, Adamo A, Putta S, Aparo A, Ferrarini I, Ugel S, Giugno R, Donadelli M, Dando I, Krampera M, Visco C, **Scupoli MT**. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression. *Sci Rep*. 2024 Mar 19;14(1):6595. doi: 10.1038/s41598-024-55728-9.PMID: 38503806.
5. Mazzerà L, Abeltino M, Lombardi G, Cantoni AM, Jottini S, Corradi A, Ricca M, Rossetti E, Armando F, Peli A, Ferrari A, Martinelli G, **Scupoli MT**, Visco C, Bonifacio M, Ripamonti A, Gambacorti-Passerini C, Bonati A, Perris R, Lunghi P. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia. *Leukemia*. 2023 Aug;37(8):1671-1685. doi: 10.1038/s41375-023-01940-x. Epub 2023 Jun 29.PMID: 37386079.
6. Danzi F, Pacchiana R, Mafficini A, **Scupoli MT**, Scarpa A, Donadelli M, Fiore A. To metabolomics and beyond: a technological portfolio to investigate cancer metabolism. *Signal Transduct Target Ther*. 2023 Mar 22;8(1):137. doi: 10.1038/s41392-023-01380-0.PMID: 36949046. Review.
7. Galasso M, Dalla Pozza E, Chignola R, Gambino S, Cavallini C, Quaglia MF, Lovato O, Dando I, Malpeli G, Krampera M, Donadelli M, Romanelli MG, **Scupoli MT**. The rs1001179 SNP and CpG methylation regulate catalase expression

in chronic lymphocytic leukemia. *Cellular and Molecular Life Sciences*. 2022 Sep 16;79(10):521. doi: 10.1007/s00018-022-04540-7.PMID:36112236.

8. Perbellini O, Cavallini C, Chignola R, Galasso M, **Scupoli MT**. Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines. *Cells*. 2022 Jun 29;11(13):2072.
9. Butera G, Manfredi M, Fiore A, Brandi J, Pacchiana R, De Giorgis V, Barberis E, Vanella V, Galasso M, **Scupoli MT**, Marengo E, Cecconi D, Donadelli M. Tumor Suppressor Role of Wild-Type P53-Dependent Secretome and Its Proteomic Identification in PDAC. *Biomolecules*. 2022 Feb 13;12(2):305.
10. Cannito S, Bincoletto V, Turato C, Pontisso P, **Scupoli MT**, Ailuno G, Andreana I, Stella B, Arpicco S, Bocca C. Hyaluronated and PEGylated Liposomes as a Potential Drug-Delivery Strategy to Specifically Target Liver Cancer and Inflammatory Cells. *Molecules*. 2022 Feb 4;27(3):1062.
11. Galasso M, Gambino S, Romanelli MG, Donadelli M, **Scupoli MT**. Browsing the oldest antioxidant enzyme: catalase and its multiple regulation in cancer. *Free Radic Biol Med*. 2021 Aug 20;172:264-272. doi: 10.1016/j.freeradbiomed.2021.06.010.
12. Cavallini C, Galasso M, Pozza ED, Chignola R, Lovato O, Dando I, Romanelli MG, Krampera M, Pizzolo G, Donadelli M, **Scupoli MT**. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. *Br J Haematol*. 2021 Jan;192(2):333-342.
13. Ambrosini G, Dalla Pozza E, Fanelli G, Di Carlo C, Vettori A, Cannino G, Cavallini C, Carmona-Carmona CA, Brandi J, Rinalducci S, **Scupoli MT**, Rasola A, Cecconi D, Palmieri M, Dando I. Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State. *Cells*. 2020 Jun 28;9(7):1572.
14. Gatti A, Buccisano F, **Scupoli MT**, Brando B. The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders. *Cytometry B Clin Cytom*. 2021 Mar;100(2):194-205.
15. Butera G, Brandi J, Cavallini C, Scarpa A, Lawlor RT, **Scupoli MT**, Marengo E, Cecconi D, Manfredi M, Donadelli M. The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells. *Biomolecules*. 2020 Jun 9;10(6):884.
16. Brozzetti L, Sacchetto L, Cecchini MP, Avesani A, Perra D, Bongianini M, Portioli C, **Scupoli M**, Ghetti B, Monaco S, Buffelli M, Zanusso G. Neurodegeneration-Associated Proteins in Human Olfactory Neurons Collected by Nasal Brushing. *Front Neurosci*. 2020 Mar 5;14:145.
17. Pandolfi L, Frangipane V, Bocca C, Marengo A, Tarro Genta E, Bozzini S, Morosini M, D'Amato M, Vitulo S, Monti M, Comolli G, **Scupoli MT**, Fattal E, Arpicco S, Meloni F. Hyaluronic Acid-Decorated Liposomes as Innovative Targeted Delivery System for Lung Fibrotic Cells. *Molecules*. 2019 Sep 10;24(18):3291.
18. Dalla Pozza E, Dando I, Pacchiana R, Liboi E, **Scupoli MT**, Donadelli M, Palmieri M. Regulation of succinate dehydrogenase and role of succinate in cancer. *Semin Cell Dev Biol*. 2019 May 1
19. Butera G, Mullappilly N, Masetto F, Palmieri M, **Scupoli MT**, Pacchiana R, Donadelli M. Regulation of Autophagy by Nuclear GAPDH and Its Aggregates in Cancer and Neurodegenerative Disorders. *Int J Mol Sci*. 2019 Apr 26;20(9).
20. Conti G, Bertossi D, Dai Prè E, Cavallini C, **Scupoli MT**, Ricciardi G, Parnigotto P, Saban Y, Sbarbati A, Nocini P. Regenerative potential of the Bichat fat pad determined by the quantification of multilineage differentiating stress enduring cells. *Eur J Histochem*. 2018 Oct 23;62(4).
21. Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal-Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, **Scupoli MT**, Donadelli M. Mutant p53 blocks SESN1/AMPK/PGC-1 α /UCP2 axis increasing mitochondrial O₂^{·-} production in cancer cells. *Br J Cancer*. 2018 Oct;119(8):994-1008.
22. Malpeli G, Barbi S, Tosadori G, Greco C, Zupo S, Pedron S, Brunelli M, Bertolaso A, **Scupoli MT**, Krampera M, Kamga PT, Croce CM, Calin GA, Scarpa A, Zamò A. MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. *Oncotarget*. 2018 Jul 3;9(51):29753-29771.
23. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, **Scupoli MT**, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. In reply to

Schäfer et al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. *Br J Haematol*. 2018 May 4.

24. Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, **Scupoli MT**, Krampera M, Kamga PT, Croce CM, Scarpa A, Zamò A. MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. *Oncotarget*. 2018 Apr 13;9(28):19961-19979.
25. Ricci V, Zonari D, Cannito S, Marengo A, **Scupoli MT**, Malatesta M, Carton F, Boschi F, Berlier G, Arpicco S. Hyaluronated mesoporous silica nanoparticles for active targeting: influence of conjugation method and hyaluronic acid molecular weight on the nanovector properties. *J Colloid Interface Sci*. 2018;516:484-497.
26. Cavallini C, Chignola R, Dando I, Perbellini O, Mimiola E, Lovato O, Laudanna C, Pizzolo G, Donadelli M, **Scupoli MT**. Low catalase expression confers redox hypersensitivity and identifies an indolent clinical behavior in CLL. *Blood*. 2018;131(17):1942-1954.
27. Parolini F, Biswas P, Serena M, Sironi F, Muraro V, Guizzardi E, Cazzoletti L, **Scupoli MT**, Gibellini D, Ugolotti E, Biassoni R, Beretta A, Malnati M, Romanelli MG, Zipeto D. Stability and Expression Levels of HLA-C on the Cell Membrane Modulate HIV-1 Infectivity. *J Virol*. 2017;92(1). pii: e01711-17.
28. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, **Scupoli MT**, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. *Br J Haematol*. 2017;178(5):781-793.
29. Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, **Scupoli MT**, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget*. 2017;8(50):86987-87001.
30. Cavallini C, Visco C, Putta S, Rossi D, Mimiola E, Purvis N, Lovato O, Perbellini O, Falisi E, Facco M, Trentin L, Romanelli MG, Semenzato G, Ambrosetti A, Gaidano G, Pizzolo G, Cesano A, **Scupoli MT**. Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemia. *Haematologica*. 2017;102(4):e144-e147.
31. Perduca M, Dalle Carbonare L, Bovi M, Innamorati G, Cheri S, Cavallini C, **Scupoli MT**, Mori A, Valenti MT. Runx2 downregulation, migration and proliferation inhibition in melanoma cells treated with BEL β -trefoil. *Oncol Rep*. 2017 Apr;37(4):2209-2214.
32. Marini O, Costa S, Bevilacqua D, Calzetti F, Tamassia N, Spina C, De Sabata D, Tinazzi E, Lunardi C, **Scupoli MT**, Cavallini C, Zoratti E, Tinazzi I, Marchetta A, Vassanelli A, Cantini M, Gandini G, Ruzzenente A, Guglielmi A, Missale F, Vermi W, Tecchio C, Cassatella MA, Scapini P. Mature CD10⁺ and immature CD10⁺ neutrophils present in G-CSF-treated donors display opposite effects on T cells. *Blood*. 2017;129(10):1343-1356.
33. Puccia S, Di Palma A, Piccaluga PP, Gemelli C, Zoratti E, Bassi G, Giacomuzzi E, Lojcono A, Borsani G, Tagliafico E, **Scupoli MT**, Bernardi S, Zanaglio C, Cattina F, Cancelli V, Malagola M, Krampera M, Marini M, Almici C, Ferrari S, Russo D. Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34⁺ cells). *PlosOne*. 2017;12(2):e0172430.
34. Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, Sartoris S, Ugel S, Vicentini C, Fassan M, Adamo A, Krampera M, **Scupoli MT**, Croce CM, Scarpa A. Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. *Oncotarget*. 2017;8(7):11809-11826.
35. Serena M, Parolini F, Biswas P, Sironi F, Blanco Miranda A, Zoratti E, **Scupoli MT**, Ziglio S, Valenzuela-Fernandez A, Gibellini D, Romanelli MG, Siccardi A, Malnati M, Beretta A, Zipeto D. HIV-1 Env associates with HLA-C free-chains at the cell membrane modulating viral infectivity. *Sci Rep*. 2017;7:40037.
36. Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G, Perbellini O, **Scupoli M**, Carli G, Facchinelli D, Cassatella M, Scapini P, Tecchio C. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. *Oncotarget*. 2016;7(19):27676-88.
37. Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, **Scupoli MT**, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. *Cancer Res*. 2016;76(9):2540-51.

38. Cavallini C, Lovato O, Bertolaso A, Zoratti E, Malpeli G, Mimiola E, Tinelli M, Aprili F, Tecchio C, Perbellini O, Scarpa A, Zamò A, Cassatella MA, Pizzolo G, **Scupoli MT**. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia. *Oncotarget*. 2015;6(31):32061-74.
39. Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, **Scupoli MT**, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival. *Oncotarget*. 2015;6(21):18653-63.
40. Perbellini O, Cioffi F, Malpeli G, Zanolin E, Lovato O, Scarpa A, Pizzolo G, **Scupoli MT**. Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2014;19:1-4.
41. Granata S, Masola V, Zoratti E, **Scupoli MT**, Baruzzi A, Messa M, Sallustio F, Gesualdo L, Lupo A, Zaza G. NLRP3 inflammasome activation in dialyzed chronic kidney disease patients. *PLoS One*. 2015;10(3):e0122272.
42. Dalla Pozza E, Dando I, Biondani G, Brandi J, Costanzo C, Zoratti E, Fassan M, Boschi F, Melisi D, Cecconi D, **Scupoli MT**, Scarpa A, Palmieri M. Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi-directionally convert into cancer stem cells. *Int J Oncol*. 2015;46(3):1099-108.
43. Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, **Scupoli MT**, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. *Haematologica*. 2014;99(5):881-7.
44. Valenti MT, Zanatta M, Donatelli L, Viviano G, Cavallini C, Scupoli MT, Dalle Carbonare L. Ascorbic acid induces either differentiation or apoptosis in MG-63 osteosarcoma lineage. *Anticancer Res*. 2014;34(4):1617-27.
45. Dalla Pozza E, Lerda C, Costanzo C, Donadelli M, Dando I, Zoratti E, **Scupoli MT**, Beghelli S, Scarpa A, Fattal E, Arpicco S, Palmieri M. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. *Biochim Biophys Acta*. 2013;1828(5):1396-404.
46. Visco C, Moretta F, Falisi E, Facco M, Maura F, Novella E, Nichele I, Finotto S, Giaretta I, Ave E, Perbellini O, Guercini N, **Scupoli MT**, Trentin L, Trimarco V, Neri A, Semenzato G, Rodeghiero F, Pizzolo G, Ambrosetti A. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. *Am J Hematol*. 2013;88(4):277-82.
47. Cavallini C, Lovato O, Bertolaso A, Pacelli L, Zoratti E, Zanolin E, Krampera M, Zamò A, Tecchio C, Cassatella MA, Pizzolo G, **Scupoli MT**. The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. *PlosOne*. 2013;8:e60136.
48. Cesano A, Perbellini O, Evensen E, Chu CC, Cioffi F, Ptacek J, Damle RN, Chignola R, Cordeiro J, Yan XJ, Hawtin RE, Nichele I, Ware JR, Cavallini C, Lovato O, Zanotti R, Rai KR, Chiorazzi N, Pizzolo G, **Scupoli MT**. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies. *Haematologica*. 2013;98(4):626-34.
49. **Scupoli MT**, Pizzolo G. Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. *Expert Rev Hematol*. 2012; 5:341-8. Review.
50. Dehecchi MC, Nicolis E, Mazzi P, Cioffi F, Bezzerri V, Lampronti I, Huang S, Wiszniewski L, Gambari R, **Scupoli MT**, Berton G, Cabrini G. Modulators of sphingolipid metabolism reduce lung inflammation. *Am J Respir Cell Mol Biol*. 2011;45(4):825-33.
51. Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, **Scupoli MT**, Pizzolo G, Krampera M. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. *Blood*. 2011;118(2):380-9.
52. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, **Scupoli MT**, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. *Cell Death and Disease*. 2011; 2, e152.
53. Dalla Pellegrina C, Perbellini O, **Scupoli MT**, Tomelleri C, Zanetti C, Zoccatelli G, Fusi M, Peruffo A, Rizzi C, Chignola R. Effects of wheat germ agglutinin on human gastrointestinal epithelium: insights from an experimental model of immune/epithelial cell interaction. *Toxicol Appl Pharmacol*. 2009;237(2):146-53.
54. Cecconi D, Donadelli M, Dalla Pozza E, Rinalducci S, Zolla L, **Scupoli MT**, Righetti PG, Scarpa A, Palmieri M. Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. *Proteomics*. 2009 Apr;9(7):1952-66.

55. Donadelli M, Dalla Pozza E, **Scupoli MT**, Costanzo C, Scarpa A, Palmieri M. Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. *Biochim Biophys Acta*. 2009;1793(2):273-80.
56. Perbellini O, **Scupoli MT**. Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens. *Expert Rev Hematol*. 2009;2(1):27-9.
57. Colombatti M, Grasso S, Porzia A, Fracasso G, **Scupoli MT**, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. *PLoS One*. 2009;4(2):e4608.
58. Donadelli M, Dalla Pozza E, Costanzo C, **Scupoli MT**, Scarpa A, Palmieri M. Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. *J Cell Biochem*. 2008;104(1):202-12.
59. **Scupoli MT**, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, and Pizzolo G. Bone marrow stromal cells up-regulate interleukin 8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF- κ B and JNK/AP-1 pathways. *Haematologica*. 2008; 93:524-532.
60. Tomelleri C, Milotti E, Dalla Pellegrina C, Perbellini O, Del Fabbro A, **Scupoli MT**, Chignola R. A quantitative study of growth variability of tumour cell clones in vitro. *Cell Prolif*. 2008;41(1):177-91.
61. Donadelli M, Costanzo C, Beghelli S, **Scupoli MT**, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. *Biochim Biophys Acta*. 2007; 1773:1095-106.
62. Cecconi D, Donadelli M, Rinalducci S, Zolla L, **Scupoli MT**, Scarpa A, Palmieri M, Righetti PG. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. *Proteomics*. 2007;7(10):1644-53.
63. **Scupoli MT**, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. *Haematologica*. 2007; 92:264-266.
64. Donadelli M, Dalla Pozza E, Costanzo C, **Scupoli MT**, Piacentini P, Scarpa A, Palmieri M. Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate. *Biochim Biophys Acta*. 2006;1763(9):917-26.
65. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, **Scupoli MT**, Guarini A, De Propriis MS, Coustan-Smith E, Campana D, Foà R, Pizzolo G. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. *Haematologica*. 2006;91(8):1109-12.
66. Krampera M, Pasini A, Rigo A, **Scupoli MT**, Tecchio C, Malpeli G, Scarpa A, Dazzi F, Pizzolo G, Vinante F. HB-EGF/HER-1 signalling in bone marrow mesenchymal stem cells: inducing cell expansion and preventing reversibly multi-lineage differentiation. *Blood*. 2005; 106: 59-66.
67. **Scupoli MT**, Vinante F, Krampera M, Vincenzi C, Nadali G, Zampieri F, Ritter MA, Eren E, Santini F, Pizzolo G. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. *Haematologica*. 2003;88:1229-1237.
68. Donadelli M, Costanzo C, Faggioli L, **Scupoli MT**, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. *Mol Carcinog*. 2003;38(2):59-69.
69. Vinante F, Rigo A, **Scupoli MT**, Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. *Blood*. 2002;99:52-60.
70. Krampera M, Fattovich G, **Scupoli MT**, Pizzolo G. Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C. *Am J Gastroenterol*. 2000;95(12):3670-3.
71. Fiorini E, Marchisio PC, **Scupoli MT**, Poffe O, Tagliabue E, Brentegani M, Colombatti M, Santini F, Tridente G, Ramarli D. Adhesion of immature and mature T cells induces in human thymic epithelial cells (TEC) activation of IL-6 gene transcription factors (NF- κ B and NF-IL6) and IL-6 gene expression: role of α 3 β 1 and α 6 β 4 integrins. *Dev Immunol*. 2000;7:195-208.
72. **Scupoli MT**, Fiorini E, Marchisio PC, Poffe O, Tagliabue E, Cecchini G, Brentegani M, Tridente G, Ramarli D. Lymphoid adhesion promotes human thymic epithelial cell survival via NF- κ B activation. *J Cell Sci*. 2000;113:169-177.

73. Ramarli D, **Scupoli MT**, Fiorini E, Poffe O, Brentegani M, Villa A, Cecchini G, Tridente G, Marchisio PC. Thymocyte contact or monoclonal antibody-mediated clustering of alpha3beta1 or alpha6beta4 integrins activate interleukin-6 (IL-6) transcription factors (NF-kappaB and NF-IL6) and IL-6 production in human thymic epithelial cells. *Blood*. 1998;92:3745-3755.
74. Achille A, **Scupoli MT**, Magalini AR, Zamboni G, Romanelli MG, Orlandini S, Biasi MO, Lemoine NR, Accolla RS, Scarpa A. APC gene mutations and allelic losses in sporadic ampullary tumours: evidence of genetic difference from tumours associated with familial adenomatous polyposis. *Int J Cancer*. 1996;68(3):305-12.
75. Paganin C, Gerosa F, Peritt D, Paiola F, Scupoli MT, Aste-Amezaga M, Frank I, Trinchieri G. Effect of interleukin-12 on the cytokine profile of human CD4 and CD8 T-cell clones. *Ann N Y Acad Sci*. 1996;795:382-3.
76. Ramarli D, Reina S, Merola M, **Scupoli MT**, Poffe O, Brentegani M, Fiorini E, Vella A, Varnier O, Tridente G. HTLV-IIIb infection of human thymic epithelial cells: viral expression correlates with the induction of NF-kappaB binding activity in cells activated by cell adhesion. *AIDS Res Hum Retrov*. 1996;12:1217-1225.
77. **Scupoli MT**, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine, NR, Scarpa A, Accolla RS. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. *Tissue Antigens*. 1996;48:301-311.
78. Gerosa F, Paganin C, Peritt D, Paiola F, **Scupoli MT**, Aste-Amezaga M, Frank I, Trinchieri G. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. *J Exp Med*. 1996;183:2559-2569.
79. **Scupoli MT**, Cestari T, Nicolis M, Cambiaggi C, Rocchi M, Accolla RS. Interspecies somatic T cell hybrids as biological tools for studying gene expression during T cell development. *Int J Clin Lab Res*. 1994;24:203-207.
80. **Scupoli MT**, Sartoris S, Nicolis N, Cestari T, Cambiaggi C, Tridente G, Accolla RS. Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen. *Immunogenetics*. 1991;40:217-221.
81. Cambiaggi C, **Scupoli MT**, Cestari T, Gerosa F, Carra G, Tridente G, Accolla RS. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. *Immunogenetics*. 1992;36(2):117-20.
82. Accolla RS, **Scupoli MT**, Cambiaggi C, Tosi G, Sartoris S. Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. *Int J Cancer Suppl*. 1991;6:20-5. Review.
83. Sartoris S, **Scupoli MT**, Scarpellino L, Paiola F, Jotterand-Bellomo M, Tridente G, Accolla RS. Inducible and constitutive MHC class II gene expression. *J Immunol*. 1990;145:1960-1967.

Patent

Patent #TO2011A000233: METODO IN VITRO DI DIAGNOSI, PROGnosi E TRATTAMENTO DI DISORDINI EMATOPOIETICI, deposited on March 11, 2011. University of Verona and Nodality Inc. (USA). Inventors: Maria Teresa SCUPOLI, Erik EVENSEN

November 21, 2025

